Deal Watch: Troubled Antibiotics Maker Cempra Exploring Strategic Options
Executive Summary
North Carolina biotech may need to conduct a 9,000-patient safety study after solithromycin was rejected by FDA, but it has $231m in cash and another Phase III candidate. Apricus is clearing financial room by transferring ex-US rights to Vivaros to Ferring, while Heat is acquiring former spinout Pelican.
You may also be interested in...
Merger With Cempra Takes Melinta Public, Will Help Launch Baxdela
In all-stock transaction, troubled Cempra will merge with privately held Melinta to create a fully integrated anti-infectives company.
Theratechnologies' Novel AIDS Drug Filed In US
Theratechnologies' partner TaiMed Biologics is seeking US approval of its novel antibody treatment for multidrug resistant HIV, ibalizumab, which offers a new therapy avenue for the increasing number of HIV patients who have worked through existing treatment options.
Start-Up Quarterly Statistics: Early Funding Declined, But Deal Dollars Flowed
A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.